BioNxt Solutions获得了新的Cladribine薄膜自免疫疾病治疗的关键专利权。 BioNxt Solutions secures key patent for a new Cladribine thin-film treatment for autoimmune diseases.

BioNxt Solutions是一家生物科学公司,收到欧洲和欧亚专利局的正面消息,确认接受其专利申请,申请用于治疗自发免疫神经疾病的亚语言Cladribine薄膜配方的专利。 BioNxt Solutions, a bioscience firm, received positive news from the European and Eurasian Patent Offices, confirming the acceptance of its patent application for a sublingual Cladribine thin-film formulation used to treat autoimmune neurological diseases. 专利涵盖化疗药物的口服溶解性输给系统。 The patent covers oral dissolvable delivery systems for chemotherapy drugs. BioNxt已在美国、加拿大、日本、澳大利亚和新西兰等主要市场申请国际专利保护,目的是确保独家经营权,增加未来的许可证发放机会。 BioNxt has filed for international patent protection in major markets including the US, Canada, Japan, Australia, and New Zealand, aiming to secure exclusivity and enhance future licensing opportunities.